LU92108I9 - - Google Patents

Info

Publication number
LU92108I9
LU92108I9 LU92108C LU92108C LU92108I9 LU 92108 I9 LU92108 I9 LU 92108I9 LU 92108 C LU92108 C LU 92108C LU 92108 C LU92108 C LU 92108C LU 92108 I9 LU92108 I9 LU 92108I9
Authority
LU
Luxembourg
Application number
LU92108C
Other languages
French (fr)
Other versions
LU92108I2 (fr
Inventor
Robert P Ryall
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23001755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92108(I9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of LU92108I2 publication Critical patent/LU92108I2/fr
Publication of LU92108I9 publication Critical patent/LU92108I9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
LU92108C 2001-01-23 2012-11-29 Menveo poudre et solution pour injection - vaccin méningococcique conjugué groupes A, C, W135 et Y LU92108I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26343501P 2001-01-23 2001-01-23

Publications (2)

Publication Number Publication Date
LU92108I2 LU92108I2 (fr) 2013-01-29
LU92108I9 true LU92108I9 (cg-RX-API-DMAC7.html) 2019-01-15

Family

ID=23001755

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92108C LU92108I2 (fr) 2001-01-23 2012-11-29 Menveo poudre et solution pour injection - vaccin méningococcique conjugué groupes A, C, W135 et Y

Country Status (38)

Country Link
US (9) US8722062B2 (cg-RX-API-DMAC7.html)
EP (3) EP2332581B1 (cg-RX-API-DMAC7.html)
JP (6) JP2005504718A (cg-RX-API-DMAC7.html)
KR (2) KR100947757B1 (cg-RX-API-DMAC7.html)
CN (1) CN100556459C (cg-RX-API-DMAC7.html)
AP (1) AP1897A (cg-RX-API-DMAC7.html)
AU (2) AU2007216743A1 (cg-RX-API-DMAC7.html)
BE (3) BE2012C050I2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0206672B8 (cg-RX-API-DMAC7.html)
CA (1) CA2435681C (cg-RX-API-DMAC7.html)
CR (1) CR7035A (cg-RX-API-DMAC7.html)
CY (2) CY1113072T1 (cg-RX-API-DMAC7.html)
DK (2) DK1355673T3 (cg-RX-API-DMAC7.html)
EA (1) EA006947B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP034701A (cg-RX-API-DMAC7.html)
ES (3) ES2388848T3 (cg-RX-API-DMAC7.html)
FR (3) FR12C0072I2 (cg-RX-API-DMAC7.html)
GE (1) GEP20053691B (cg-RX-API-DMAC7.html)
HR (1) HRP20030598B1 (cg-RX-API-DMAC7.html)
HU (2) HU230490B1 (cg-RX-API-DMAC7.html)
IL (3) IL157060A0 (cg-RX-API-DMAC7.html)
IS (1) IS6881A (cg-RX-API-DMAC7.html)
LT (1) LT5177B (cg-RX-API-DMAC7.html)
LU (1) LU92108I2 (cg-RX-API-DMAC7.html)
LV (1) LV13128B (cg-RX-API-DMAC7.html)
MX (2) MXPA03006561A (cg-RX-API-DMAC7.html)
NO (1) NO20033816L (cg-RX-API-DMAC7.html)
NZ (2) NZ622900A (cg-RX-API-DMAC7.html)
OA (1) OA12590A (cg-RX-API-DMAC7.html)
PL (1) PL226184B1 (cg-RX-API-DMAC7.html)
PT (2) PT1355673E (cg-RX-API-DMAC7.html)
RO (1) RO122761B1 (cg-RX-API-DMAC7.html)
SI (1) SI21352A (cg-RX-API-DMAC7.html)
TN (1) TNSN03041A1 (cg-RX-API-DMAC7.html)
UA (1) UA92579C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002058737A2 (cg-RX-API-DMAC7.html)
YU (1) YU66103A (cg-RX-API-DMAC7.html)
ZA (1) ZA200306176B (cg-RX-API-DMAC7.html)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP2332581B1 (en) 2001-01-23 2015-07-01 Sanofi Pasteur Inc. Tri- or tetravalent meningococcal polysaccharide-CRM197 conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2014218428B2 (en) * 2001-06-20 2016-08-25 Glaxosmithkline Biologicals Sa Capsular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
AU2003299501A1 (en) * 2002-05-16 2004-05-04 Aventis Pasteur, Inc. Animal component free meningococcal polysaccharide fermentation and seedbank development
AU2003257003A1 (en) * 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
BR0316271A (pt) * 2002-11-14 2005-10-11 Inst Finlay Ct De Investigacio Método para a obtenção de preparados vacinais conjugados multivalentes, composição vacinal multivalente e uso da mesma
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CN102302776B (zh) 2003-01-30 2014-06-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
BRPI0408167B1 (pt) * 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais
AU2004255526A1 (en) * 2003-05-07 2005-01-20 Aventis Pasteur, Inc. Method of enhanced immunogenicity to meningococcal vaccination
EP2179729B1 (en) * 2003-06-02 2016-07-20 GlaxoSmithKline Biologicals SA Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
EP2851088A1 (en) * 2003-06-23 2015-03-25 Baxter International Inc. Vaccines against group Y Neisseria meningitidis and meningoccal combinations thereof
AU2004251742A1 (en) * 2003-06-23 2005-01-06 Sanofi Pasteur, Inc. Immunization method against Neisseria meningitidis serogroups A and C
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CN103405761A (zh) 2003-10-02 2013-11-27 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
GB0406013D0 (en) * 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
AU2011204789B2 (en) * 2004-04-22 2013-07-11 Glaxosmithkline Biologicals S.A. Immunising against meningococcal serogroup Y using proteins
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
NZ550533A (en) * 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP2351582A1 (en) * 2004-08-30 2011-08-03 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
MX2007003292A (es) * 2004-09-21 2007-09-07 Sanofi Pasteur Inc Conjugados y vacuna con proteinas de polisacarido derivadas meningococales multivalentes.
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
JP2008536515A (ja) 2005-04-18 2008-09-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド ワクチンの調製のためのｂ型肝炎ウイルス表面抗原の発現
DK2283857T3 (da) 2005-06-27 2019-10-28 Glaxosmithkline Biologicals Sa Vaccinesammensætning omfattende konjugerede native N. Meningitidis kapselpolysaccharider
CA2621023C (en) 2005-09-01 2019-07-02 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup c meningococcus
US20070065462A1 (en) * 2005-09-21 2007-03-22 Ryall Robert P Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
EP1993604B1 (en) * 2006-03-17 2015-12-02 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Methods for preparing complex multivalent immunogenic conjugates
US20080026002A1 (en) * 2006-03-22 2008-01-31 Lisa Danzig Regimens for immunisation with meningococcal conjugates
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
WO2007116409A2 (en) 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
ES2555786T3 (es) 2007-06-04 2016-01-08 Glaxosmithkline Biologicals Sa Formulación de vacunas contra la meningitis
ATE553774T1 (de) 2007-10-19 2012-05-15 Novartis Ag Meningokokkenimpfstoffformulierungen
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
US8003112B2 (en) * 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
WO2011080595A2 (en) * 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
AU2011288203A1 (en) 2010-03-18 2012-08-23 Novartis Ag Adjuvanted vaccines for serogroup B meningococcus
FI2608805T4 (fi) 2010-08-23 2025-08-07 Wyeth Llc NEISSERIA MENINGITIDIS rLP2086 -ANTIGEENIEN STABIILEJA FORMULAATIOITA
WO2012031271A1 (en) 2010-09-04 2012-03-08 Novartis Ag Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
CN103764171B (zh) 2011-07-08 2016-08-17 诺华股份有限公司 酪氨酸连接方法
CA2854934A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX351993B (es) 2012-03-09 2017-11-03 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
CN102660602B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
BR112014029313A2 (pt) 2012-05-22 2017-06-27 Novartis Ag conjugado de meningococos do sorogrupo x
HUE049531T2 (hu) * 2012-08-16 2020-10-28 Pfizer Glikokonjugációs eljárások és kompozíciók
AU2013311702A1 (en) 2012-09-06 2015-02-19 Novartis Ag Combination vaccines with serogroup B meningococcus and D/T/P
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
CA2894260A1 (en) 2012-12-18 2014-06-26 Glaxosmithkline Biologicals S.A. Conjugates for protecting against diphtheria and/or tetanus
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
JP6747968B2 (ja) * 2013-03-18 2020-08-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 治療方法
US9359400B2 (en) 2013-07-11 2016-06-07 Novartis Ag Site-specific chemoenzymatic protein modifications
MX380129B (es) 2013-09-08 2025-03-11 Pfizer Composiciones de neisseria meningitidis y sus metodos
EP3148577B1 (en) 2014-05-24 2021-01-20 Biological E Limited Novel semi-synthetic meningococcal conjugate vaccine
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
EP3258850B1 (en) 2015-02-20 2020-06-24 Bayer HealthCare LLC Contrast imaging agent with dissolved gas-evolving fluid
KR20160011136A (ko) 2015-03-25 2016-01-29 한국기계연구원 내식성이 향상된 마그네슘 합금 및 이를 이용하여 제조한 마그네슘 합금 부재의 제조방법
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
ES2924040T3 (es) 2015-12-30 2022-10-04 Ascendis Pharma As Autoinyector con sistema de retención de cartucho
KR102204927B1 (ko) 2016-07-25 2021-01-19 에스케이바이오사이언스(주) 피막 다당류-단백질 접합 백신의 품질 평가 방법
WO2018045286A1 (en) 2016-09-02 2018-03-08 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
IL267733B2 (en) 2017-01-31 2023-10-01 Pfizer Neisseria meningitidis compositions and methods thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
WO2020055788A1 (en) 2018-09-12 2020-03-19 Bayer Healthcare Llc System for conducting a fluid injection procedure
EP3632465A1 (en) 2018-10-03 2020-04-08 Sanofi Pasteur Inc. Combined immunization against meningococcal disease and human papillomavirus
US12005110B2 (en) 2019-02-14 2024-06-11 University Of Florida Research Foundation, Incorporated Honeybee commensal Snodgrassella alvi vaccine against pathogenic Neisseriaceae
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
CN110903388B (zh) * 2019-12-03 2024-01-02 兰州生物制品研究所有限责任公司 一种将脑膜炎球菌抗血清去交叉反应的方法
ES3029414T3 (en) 2019-12-17 2025-06-24 9286 3620 Quebec Inc Oral delivery systems based on in situ forming protein/polysaccharide coacervates
KR102610292B1 (ko) 2021-02-10 2023-12-04 에스케이바이오사이언스(주) 스트랩토코커스 뉴모니애 다당류와 운반체 단백질의 접합체 제조 방법
TW202245836A (zh) 2021-02-19 2022-12-01 美商賽諾菲巴斯德公司 重組ｂ型腦膜炎球菌疫苗
JP2025512330A (ja) 2022-04-11 2025-04-17 サノフィ パスツール インコーポレイテッド シアノ水素化ホウ素ナトリウムとのタンパク質－糖コンジュゲーション
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
CN120380281A (zh) 2023-08-09 2025-07-25 拜耳医药保健有限责任公司 用于肺功能和结构成像的惰性气体递送设备、药筒和触发系统

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351761A (en) 1978-05-15 1982-09-28 Research Corporation Purified antigen to test for Neisseria gonorrhoeae antibodies
US4404371A (en) 1981-01-14 1983-09-13 Battelle Memorial Institute Carboxymethylcellulose with carbonate bridges and preparation thereof
US4351762A (en) * 1981-03-10 1982-09-28 Bioresearch, Inc. Rapid, quantitative peptide synthesis using mixed anhydrides
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
DE3382737T2 (de) 1982-11-10 1994-05-19 Mitsubishi Heavy Ind Ltd Nickel-Chrom-Legierung.
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
EP0200249B1 (en) 1985-04-17 1988-10-19 Akzo N.V. Method of applying a road marking composition
DE3518706A1 (de) 1985-05-24 1986-11-27 Kernforschungszentrum Karlsruhe Gmbh, 7500 Karlsruhe Verfahren zur herstellung von formkoerpern mit verbesserten, isotropen eigenschaften
US4814276A (en) * 1986-04-25 1989-03-21 Becton, Dickinson And Company Selective medium for growth of neisseria
JP3436756B2 (ja) 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
US4963534A (en) 1989-05-19 1990-10-16 Merck & Co., Inc. Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents
NZ239643A (en) 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
WO1992016232A1 (en) 1991-03-12 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Polysaccharide-protein conjugates
HU9400426D0 (en) 1991-08-16 1994-05-30 Merck & Co Inc Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
US5314811A (en) * 1992-07-13 1994-05-24 Merck & Co., Inc. Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
US5422427A (en) 1991-09-17 1995-06-06 The United States Of America As Represented By The United States Department Of Health And Human Services Pneumococcal fimbrial protein A
FR2682388B1 (fr) 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
RU2160120C2 (ru) * 1992-05-23 2000-12-10 Смитклайн Бичам Байолоджикалс С.А. Комбинированная вакцина на основе поверхностного антигена вируса гепатита в, способ ее получения и способ предупреждения инфекции гепатита в у человека
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
ES2171418T3 (es) * 1992-08-31 2002-09-16 Baxter Healthcare Sa Vacunas contra neisseria meningitidis del grupo c.
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
JP4233113B2 (ja) 1995-06-07 2009-03-04 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム 多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
EA199700413A1 (ru) 1995-06-23 1998-08-27 Смитклайн Бичам Байолоджикалз, С.А. Композиция, содержащая вакцину и конъюгат антигена и полисахарида, адсорбированные на фосфате алюминия
US20020054884A1 (en) * 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
CA2246760C (en) * 1997-01-21 2012-01-10 Pasteur Merieux Serums & Vaccins Polysaccharide-peptide-conjugates
WO1998032873A1 (de) 1997-01-24 1998-07-30 Schweiz. Serum- & Impfinstitut Bern Neues verfahren zur isolierung von polysacchariden
US6403306B1 (en) * 1997-04-09 2002-06-11 Emory University Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto
WO1998047530A2 (en) 1997-04-24 1998-10-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
EP1849860B1 (en) 1997-05-28 2010-11-17 Novartis Vaccines and Diagnostics S.r.l. Process for preparing an immunogenic factor of Corynebacterium diphtheriae using a culture medium with yeast extract as aminoacid source and no protein complexes of animal origin
JP2002506448A (ja) * 1997-06-24 2002-02-26 カイロン コーポレイション 抗髄膜炎菌ワクチン組成物を使用して成体を免疫する方法
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
WO1999032653A1 (en) 1997-12-23 1999-07-01 North American Vaccine, Inc. Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugates vaccines
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
KR100711561B1 (ko) 1999-02-01 2007-04-27 에-자이가부시기가이샤 면역학적 보조제 화합물
EP1162999B1 (en) * 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
WO2000071725A2 (en) 1999-05-19 2000-11-30 Chiron S.P.A. Combination neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
EP1233784B1 (en) 1999-12-02 2008-07-09 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for stabilizing biological molecules upon lyophilization
US6800455B2 (en) * 2000-03-31 2004-10-05 Scios Inc. Secreted factors
WO2002000249A2 (en) 2000-06-29 2002-01-03 Glaxosmithkline Biologicals S.A. Multivalent vaccine composition
EP2332581B1 (en) * 2001-01-23 2015-07-01 Sanofi Pasteur Inc. Tri- or tetravalent meningococcal polysaccharide-CRM197 conjugate vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination

Also Published As

Publication number Publication date
BRPI0206672B1 (pt) 2018-11-06
US20130224241A1 (en) 2013-08-29
LU92108I2 (fr) 2013-01-29
FR12C0072I1 (cg-RX-API-DMAC7.html) 2013-01-04
US20130177588A1 (en) 2013-07-11
US20150174259A1 (en) 2015-06-25
EP1355673B1 (en) 2012-05-30
NO20033816L (no) 2003-09-11
CY2012030I1 (el) 2015-08-05
US20030068336A1 (en) 2003-04-10
ES2544979T3 (es) 2015-09-07
CN1610560A (zh) 2005-04-27
WO2002058737A2 (en) 2002-08-01
JP2014043474A (ja) 2014-03-13
IL225522A0 (en) 2013-06-27
IS6881A (is) 2003-07-22
FR12C0072I2 (fr) 2013-11-01
OA12590A (en) 2006-06-08
DK1355673T3 (da) 2012-09-17
IL225522A (en) 2016-04-21
FR22C1001I2 (fr) 2025-02-07
EP1355673A2 (en) 2003-10-29
US20160000928A1 (en) 2016-01-07
SI21352A (sl) 2004-06-30
MXPA03006561A (es) 2004-10-15
US20190060475A1 (en) 2019-02-28
US8722062B2 (en) 2014-05-13
LT2003071A (en) 2004-08-25
US9173955B2 (en) 2015-11-03
US20180154010A1 (en) 2018-06-07
US10143757B2 (en) 2018-12-04
TNSN03041A1 (en) 2005-12-23
YU66103A (sh) 2006-05-25
US8999354B2 (en) 2015-04-07
HU230490B1 (hu) 2016-08-29
AP2003002829A0 (en) 2003-09-30
US8741314B2 (en) 2014-06-03
IL157060A0 (en) 2004-02-08
AU2010219288A1 (en) 2010-09-23
CA2435681C (en) 2011-06-21
NZ622900A (en) 2015-11-27
HUS1600040I1 (hu) 2019-05-28
JP2005504718A (ja) 2005-02-17
JP2016128526A (ja) 2016-07-14
UA92579C2 (ru) 2010-11-25
US20130216571A1 (en) 2013-08-22
JP2011140522A (ja) 2011-07-21
HRP20030598B1 (hr) 2013-05-31
EP2957300B1 (en) 2021-07-14
HUP0302999A2 (hu) 2003-12-29
NZ602682A (en) 2014-05-30
US20140308311A1 (en) 2014-10-16
EP2957300A2 (en) 2015-12-23
NO20033816D0 (no) 2003-08-27
BRPI0206672B8 (pt) 2021-05-25
KR20030084913A (ko) 2003-11-01
HUP0302999A3 (en) 2011-05-30
KR20090029857A (ko) 2009-03-23
JP5795721B2 (ja) 2015-10-14
PL373710A1 (en) 2005-09-05
EP2332581B1 (en) 2015-07-01
CR7035A (es) 2008-11-25
JP2014043475A (ja) 2014-03-13
JP2014065745A (ja) 2014-04-17
ZA200306176B (en) 2005-03-30
BE2022C502I2 (cg-RX-API-DMAC7.html) 2023-04-12
US10617766B2 (en) 2020-04-14
HRP20030598A2 (en) 2005-06-30
PT2332581E (pt) 2015-10-16
BE2012C050I2 (cg-RX-API-DMAC7.html) 2021-03-23
FR15C0094I1 (cg-RX-API-DMAC7.html) 2016-01-22
FR15C0094I2 (fr) 2017-05-19
RO122761B1 (ro) 2010-01-29
EA006947B1 (ru) 2006-06-30
BE2015C077I2 (cg-RX-API-DMAC7.html) 2021-02-04
CN100556459C (zh) 2009-11-04
ES2892316T3 (es) 2022-02-03
US9844601B2 (en) 2017-12-19
EP2957300A3 (en) 2016-03-30
AU2007216743A1 (en) 2007-10-04
ECSP034701A (es) 2003-10-28
CA2435681A1 (en) 2002-08-01
LV13128B (en) 2004-07-20
BR0206672A (pt) 2005-05-10
CY2012030I2 (el) 2016-08-31
PT1355673E (pt) 2012-08-31
EP2332581A1 (en) 2011-06-15
EA200300827A1 (ru) 2004-06-24
DK2332581T3 (en) 2015-10-05
ES2388848T3 (es) 2012-10-19
GEP20053691B (en) 2005-12-12
IL157060A (en) 2013-04-30
KR100947751B1 (ko) 2010-03-18
AP1897A (en) 2008-10-10
US8734813B2 (en) 2014-05-27
WO2002058737A3 (en) 2003-05-22
CY1113072T1 (el) 2015-08-05
LT5177B (lt) 2004-11-25
FR22C1001I1 (fr) 2022-02-18
KR100947757B1 (ko) 2010-03-18
PL226184B1 (pl) 2017-06-30
MX341760B (es) 2016-09-02

Similar Documents

Publication Publication Date Title
BE2022C531I2 (cg-RX-API-DMAC7.html)
BE2022C547I2 (cg-RX-API-DMAC7.html)
BE2022C502I2 (cg-RX-API-DMAC7.html)
BE2017C059I2 (cg-RX-API-DMAC7.html)
BE2017C055I2 (cg-RX-API-DMAC7.html)
BE2017C051I2 (cg-RX-API-DMAC7.html)
BE2017C032I2 (cg-RX-API-DMAC7.html)
BE2016C051I2 (cg-RX-API-DMAC7.html)
BE2015C046I2 (cg-RX-API-DMAC7.html)
FR14C0064I1 (cg-RX-API-DMAC7.html)
BE2014C036I2 (cg-RX-API-DMAC7.html)
IN2004KO00171A (cg-RX-API-DMAC7.html)
JP2001358989A5 (cg-RX-API-DMAC7.html)
BE2017C050I2 (cg-RX-API-DMAC7.html)
JP2002000874A5 (cg-RX-API-DMAC7.html)
JP2001330560A5 (cg-RX-API-DMAC7.html)
BRPI0204884B1 (cg-RX-API-DMAC7.html)
CH1379220H1 (cg-RX-API-DMAC7.html)
JP2001223590A5 (cg-RX-API-DMAC7.html)
BRPI0101486B8 (cg-RX-API-DMAC7.html)
JP2001255394A5 (cg-RX-API-DMAC7.html)
JP2002141964A5 (cg-RX-API-DMAC7.html)
BRPI0210463A2 (cg-RX-API-DMAC7.html)
AU2000280389A8 (cg-RX-API-DMAC7.html)
JP2002229306A5 (cg-RX-API-DMAC7.html)